2019 American Transplant Congress
Evaluation of the Safety and Tolerability of Clazakizumab® (Anti-IL-6 Monoclonal) as a Desensitization Agent in Highly-HLA Sensitized ESRD Patients (nct03380962)
Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: Currently, there is growing interest in development of novel immune-modulatory drugs likely to improve allo-antibody reduction in transplantation. Clazakizumab (Vitaeris Inc.) is a humanized…2019 American Transplant Congress
Quantifying Differential Infection Risks in HLA- and/or ABO- Incompatible Kidney Transplant Recipients
1Johns Hopkins, Baltimore, MD, 2New York University, New York, NY
*Purpose: Desensitization has enabled kidney transplantation across HLA-and/or ABO barriers and has conferred survival benefit to patients who lack compatible living donors (CLDKT). However, due…2019 American Transplant Congress
Successful Use of Nonantigen Specific Immunoadsorption In ABO-Incompatible Desensitization and Humoral Rejection Treatment in Kidney Transplantation
Servei de Nefrologia i Trasplantament Renal, Hospital Clínic de Barcelona, Barcelona, Spain
*Purpose: : Immunoadsorption (IA) is an apheresis procedure that has been shown to be effective in the ABO incompatible living donor kidney transplantation (ABOi LDKT)…2019 American Transplant Congress
Outcomes after Prolonged Therapeutic Plasma Exchange in Pediatric Kidney Transplant Patients with Early Recurrence of Focal Segmental Glomerular Sclerosis
*Purpose: Focal segmental glomerular sclerosis (FSGS) is the most common cause of glomerulonephritis leading to end-stage renal disease (ESRD) in pediatric patients. FSGS recurs frequently…2019 American Transplant Congress
Osmotic Demyelination Syndrome after Liver Transplantation- Etiology and Treatment Options
*Purpose: Orthotopic liver transplantation (OLT) is the only effective therapy for patients with end stage liver failure that increases long-term survival, but is not without…2019 American Transplant Congress
Is Pre-transplant Plasmapheresis For Patients With Insignificant Abo Blood Type Antibody In Abo Blood Type Incompatible Kidney Transplant Necessary? – A Japanese Single Center Study.
Urology and Kidney Transplant Surgery, Sapporo City General Hospital, Sapporo, Hokkaido, Japan
*Purpose: ABO incompatible kidney donor (ABOiKT) is still precious to fill up the extremely organ donor shortages in our country. Though plasmaphresis (PP) as desensitization…2018 American Transplant Congress
Acute Antibody Mediated Rejection Treatment Impact on Class I and Class II Anti-HLA Antibodies in Pediatric Kidney Transplant Recipients
Purpose: Characterize class I and class II donor specific antibodies (DSA) response to acute antibody mediated rejection (AMR) treatment in pediatric kidney transplant recipients (KTR).Methods:…2018 American Transplant Congress
Recurrence of Focal Segmental Glomerulosclerosis (FSGS) and Response to Prolonged Plasmapheresis Therapy: A Single Center Pediatric Experience
FSGS is the most common glomerular cause of ESKD in pediatric patients. The risk of recurrence after kidney transplant (KT) is 30-60%, and half of…2018 American Transplant Congress
Efficacy and Safety of Acute Antibody Rejection Treatment in Pediatric Kidney Transplant Recipients
Purpose: Evaluate the efficacy and safety of acute antibody mediated rejection (AMR) treatment modalities in pediatric kidney transplant recipients (KTR).Methods: A single-center retrospective chart review…2018 American Transplant Congress
Preemptive Plasma Therapy and Eculizumab (ECU) Rescue for Atypical Hemolytic Uremic Syndrome (aHUS) Relapse Following Kidney Transplantation (KTX)
Introduction: KTX in aHUS patients is associated with a high rate of relapse and graft loss. Here, we report on seven aHUS cases with end-stage…
American Transplant Congress abstracts